What Jardiance (Empagliflozin) Is Used For
Jardiance is FDA-approved for improving blood sugar control in adults with type 2 diabetes and reducing cardiovascular death in diabetic patients with established cardiovascular disease, but its most clinically significant use based on mortality and morbidity outcomes is for treating heart failure (both reduced and preserved ejection fraction) and chronic kidney disease, regardless of diabetes status. 1
FDA-Approved Indications
Jardiance has two official FDA indications 1:
- Type 2 diabetes management: As an adjunct to diet and exercise to improve glycemic control in adults
- Cardiovascular death reduction: In adult patients with type 2 diabetes and established cardiovascular disease
Important limitation: Jardiance is NOT recommended for type 1 diabetes or diabetic ketoacidosis treatment 1
Evidence-Based Clinical Uses (Guideline-Supported)
Heart Failure Treatment (Primary Indication by Outcomes)
Jardiance significantly reduces cardiovascular death and heart failure hospitalization in patients with heart failure, with or without diabetes 2. This represents the strongest mortality benefit:
- Heart failure with reduced ejection fraction (HFrEF): 35% reduction in heart failure hospitalization, with consistent mortality benefits 2
- Heart failure with preserved ejection fraction (HFpEF): 21% reduction in composite cardiovascular death or heart failure hospitalization (HR 0.79,95% CI 0.69-0.90) 2, 3
- Benefits occur regardless of diabetes status 2, 4
The 2025 ADA guidelines and 2022 AHA/ACC/HFSA guidelines now position SGLT2 inhibitors like empagliflozin as foundational therapy for heart failure 5, 3.
Chronic Kidney Disease Protection
Empagliflozin reduces CKD progression and cardiovascular events in patients with eGFR ≥20 mL/min/1.73 m² and albuminuria 6:
- 50% reduction in composite renal outcomes (chronic dialysis, transplantation, or sustained eGFR reduction; HR 0.50,95% CI 0.32-0.77) 2
- Slows eGFR decline over time 6, 7
- Reduces macroalbuminuria and microalbuminuria progression 7
- Benefits extend to patients with or without diabetes 6, 4
Cardiovascular Risk Reduction in Type 2 Diabetes
In the EMPA-REG OUTCOME trial, empagliflozin demonstrated 8, 2, 9:
- 14% reduction in major adverse cardiovascular events (MACE)
- 38% reduction in cardiovascular death
- 32% reduction in all-cause mortality
These benefits were specifically in diabetic patients with established cardiovascular disease 8, 9.
Mechanism and Additional Effects
Empagliflozin works by blocking glucose reabsorption in the kidney (SGLT2 inhibition), producing 5, 7:
- Glycemic control: HbA1c reduction of 0.5-0.8% 5, 7
- Weight loss: Approximately 2 kg reduction 8, 5
- Blood pressure reduction: Systolic ~4 mmHg, diastolic ~2 mmHg 8, 5
- Low hypoglycemia risk when used alone 5
Dosing Considerations
Standard dose: 10 mg once daily (the dose tested in cardiovascular and renal outcomes trials) 8, 5
- 25 mg daily may provide additional glucose lowering but no additional cardiovascular or renal benefit 8
- Glucose-lowering effect diminishes with eGFR <45 mL/min/1.73 m², but continue for cardiovascular and kidney benefits until dialysis 5
- Can be initiated with eGFR >30 mL/min/1.73 m² (some trial data support use down to eGFR 20) 6
Key Safety Considerations
- Genital mycotic infections (10-15% in women, lower in men)
- Urinary tract infections (monitor in elderly ≥75 years: 15-16% incidence)
- Volume depletion (especially in elderly ≥75 years: 4.4% with 25 mg dose)
Serious but rare risks 5:
- Diabetic ketoacidosis (including euglycemic DKA): Discontinue 3-4 days before surgery and during critical illness
- Fournier's gangrene (necrotizing fasciitis): Rare but requires prompt treatment
- Acute kidney injury: Monitor kidney function, especially with volume depletion
- Severe renal impairment (eGFR <30 mL/min/1.73 m² per label, though evidence supports use to eGFR 20)
- End-stage renal disease or dialysis
- Type 1 diabetes (increased DKA risk)
Clinical Positioning
The 2025 ADA Standards of Care prioritize empagliflozin for patients with 5:
- Type 2 diabetes with heart failure (any ejection fraction)
- Type 2 diabetes with chronic kidney disease (eGFR ≥20, albuminuria present)
- Type 2 diabetes with established atherosclerotic cardiovascular disease
The 2021 CCS/CHFS guidelines recommend SGLT2 inhibitors like empagliflozin as foundational therapy for all patients with HFrEF, regardless of diabetes status 4.
The drug's value extends far beyond glucose control—its primary clinical utility is preventing cardiovascular death, heart failure hospitalization, and kidney disease progression 2.